A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies

Inclusion Criteria:

- Patients with biopsy proven B-cell malignancies [e.g. chronic lymphocytic leukemia
(CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM)]; HIV-associated lymphomas
and acute leukemias are not eligible

- Performance status: ECOG 0, 1, or 2

- Life expectancy of at least 12 weeks

- Patients with aggressive NHL will be enrolled after having failed all possible
therapy with curative intent

- Patients with CLL must have failed an alkylating agent-containing regimen as well as
fludarabine chemotherapy

- Patients with multiple myeloma must have received at least one prior chemotherapy
regimen and not be eligible for a dose intensification treatment approach

- At least 4 weeks must have elapsed since prior large-field radiation therapy

- Patients must have been off previous anti-cancer therapy for at least 3 weeks (6
weeks for BCNU and mitomycin C) and recovered from all treatment related toxicity

- Prior vincristine therapy is allowed

- Sexually active men and women must use an accepted and effective method of
contraception

- In women of child-bearing age, a pregnancy test may be done at the discretion of the
investigator

- Must have given written informed consent

Exclusion Criteria:

- Patients with brain metastasis, leptomeningeal involvement, primary CNS NHL, and
acute leukemia are ineligible

- Patients with HIV infection are ineligible

- WBC < 3000/ul

- Granulocytes < 1500/ul

- Platelets < 50,000/ul

- Hemoglobin =< 8.5 g/dl

- Bilirubin > 1.5 mg/dl

- AST and ALT > 2 times normal

- Creatinine > 2.0 mg/dl, and/or actual creatinine clearance < 40 ml/min/1.73 m^2; all
patients are required to have a 24 hr creatinine clearance

- Clinical evidence of bleeding diathesis

- ECOG Performance status 3 or 4

- Patients who are pregnant or lactating; vincristine can cause fetal harm

- Patients with clinically apparent neuropathy are ineligible (>= grade 2 neuropathy)